- Home
- GENK vs FGEN Comparison
GENK vs FGEN Comparison
Compare GENK & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- FGEN
- Stock Information
- Founded
- GENK 2011
- FGEN 1993
- Country
- GENK United States
- FGEN United States
- Employees
- GENK N/A
- FGEN N/A
- Industry
- GENK Restaurants
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- FGEN Health Care
- Exchange
- GENK Nasdaq
- FGEN Nasdaq
- Market Cap
- GENK 36.5M
- FGEN 34.5M
- IPO Year
- GENK 2023
- FGEN 2014
- Fundamental
- Price
- GENK $5.70
- FGEN $0.48
- Analyst Decision
- GENK Strong Buy
- FGEN
- Analyst Count
- GENK 3
- FGEN 0
- Target Price
- GENK $13.17
- FGEN N/A
- AVG Volume (30 Days)
- GENK 55.8K
- FGEN 778.1K
- Earning Date
- GENK 03-05-2025
- FGEN 02-24-2025
- Dividend Yield
- GENK N/A
- FGEN N/A
- EPS Growth
- GENK 483.78
- FGEN N/A
- EPS
- GENK 0.17
- FGEN N/A
- Revenue
- GENK $198,834,000.00
- FGEN $180,015,000.00
- Revenue This Year
- GENK $14.66
- FGEN $21.91
- Revenue Next Year
- GENK $21.47
- FGEN N/A
- P/E Ratio
- GENK $33.14
- FGEN N/A
- Revenue Growth
- GENK 12.50
- FGEN 16.15
- 52 Week Low
- GENK $5.50
- FGEN $0.18
- 52 Week High
- GENK $14.46
- FGEN $2.80
- Technical
- Relative Strength Index (RSI)
- GENK 16.35
- FGEN 45.00
- Support Level
- GENK $6.32
- FGEN $0.46
- Resistance Level
- GENK $6.42
- FGEN $0.52
- Average True Range (ATR)
- GENK 0.34
- FGEN 0.04
- MACD
- GENK -0.06
- FGEN -0.01
- Stochastic Oscillator
- GENK 11.66
- FGEN 25.86
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc is an Asian casual dining restaurant in the United States. It offers an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.